Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cancerous Target Equipment & Supplies In Europe
118 equipment items found
Premium
Manufactured by:Vobis LLC based inEaston, PENNSYLVANIA (USA)
We have developed proprietary lipid based nano technologies that have potential benefits in different therapeutic areas including targeted cancer therapy, DNA Vaccination and liver diseases. Here are the some of the highlights related to our LNP and liposomal experience including type of liposomes and techniques. ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: New Formulation. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
by:Astraveus based inParis, FRANCE
They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including 61Cu for diagnostics and 67Cu for therapeutics, are integral in developing highly precise ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI refined and improved ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:VECT-HORUS based inMARSEILLE, FRANCE
Vect-Horus has developed its “VECTrans®” breakthrough technology platform with the objective of making the ‘undruggable’ druggable by overcoming challenges of the BBB, and more generally biological barriers. VECTrans® is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target ...
Manufactured by:leadXpro AG based inVilligen, SWITZERLAND
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
Manufactured by:Reglagene Holding, Inc. based inTucson, ARIZONA (USA)
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...
Manufactured by:SurgiMab based inMontpellier, FRANCE
SGM-201 is a preclinical stage product based on the same technique that targets ovarian cancer. Both allow surgeons to visualize tumors in real-time with a near-infrared camera, helping them to perform more radical cytoreductive surgery, thus automatically improving surgical outcomes. ...